Administration of Venetoclax to Promote Apoptosis of HIV-infected Cells and Reduce the Size of the HIV Reservoir Among People Living With HIV on ART

• Status: Not yet recruiting
• Trial end date: 2024-10-01

Summary

In summary, there is a compelling rationale for investigating venetoclax as an intervention to sensitise virus-expressing cells to apoptosis and thereby reduce the size of the latent HIV reservoir. While this concept may ultimately need to be tested in the setting of concomitant latency reversal, we here propose to initially establish the safety of venetoclax in PLWH on ART. We will use this study to also investigate effects of venetoclax monotherapy on proapoptotic pathways, immune effector function and HIV persistence in PLWH on ART and through these studies establish the rationale for subsequent studies testing venetoclax in combination with an LRA.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: University of Aarhus
• Collaborators: Aarhus University Hospital; The Alfred; The Peter Doherty Institute for Infection and Immunity; Walter and Eliza Hall Institute of Medical Research
• Treatments: Venetoclax